Sedana Medical AB (OSTO:SEDANA)

Q4 2025 Sedana Medical AB (publ) Earnings Call Transcript

Feb 12, 2026 / 12:30 PM GMT

Release Date Price: kr10.68 (+11.72%)

Transcript

Key Points

Positve

Sedana Medical AB (OSTO:SEDANA) achieved a positive EBITDA in its ex-US business for the first time in 2025, marking a significant turnaround from previous losses.
The company reported a 16% year-over-year sales growth, with 12% being organic, reaching an all-time high in sales for the full year.
Gross margin improved to 73% in Q4 2025, aided by cost reductions from the acquisition of a supplier in Malaysia.
Sedana Medical AB (OSTO:SEDANA) made significant progress in the US market, with pivotal trials meeting primary endpoints and the FDA authorizing an early access program.
The company has successfully expanded its market presence beyond Germany, with direct markets outside Germany showing a 32% growth for the full year.

Negative

The UK market faced challenges due to temporary staff absences, leading to a flat development in 2025.
In France, sales were almost flat for the full year due to a decline in customers using off-label sevoflurane.
Germany experienced a mixed performance with a sales decline of 7% in the second half of 2025 due to lower ICU occupancy rates.
The company's cash position decreased from 112 million SEK at the end of Q3 to 91 million SEK at the end of 2025, driven by investments in intangible assets.
The timeline for US market approval and launch is uncertain, with potential delays depending on the FDA's review process and priority review status.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

SEDANA.ST - Sedana Medical AB (publ)
Q4 2025 Sedana Medical AB (publ) Earnings Call
Feb 12, 2026 / 12:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Hello and welcome to today's Finwire broadcast presentation with Sedana Medical. After the presentation, there will be a question-and-answer session. So if you have any questions, you can submit them using the form on the right. In case you are following the report with the phone, you can push 9 on your telephone keypad to raise your hand and 6 to lower the hand. With that said, I'll hand the floor to you. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you for the introduction and a warm welcome to our Q4 and full year report 2025. This, report

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.